Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 2-Month TB prevention be as good as 4 months?

NCT ID NCT03988933

Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking a higher dose of the drug rifampin for 2 months is as safe and effective as the standard 4-month dose for treating latent tuberculosis (TB) infection. Over 1,300 adults and children aged 10 and older with latent TB were randomly assigned to receive either the standard dose for 4 months, or a double or triple dose for 2 months. The goal is to find a shorter, easier-to-complete treatment that prevents latent TB from becoming active.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rifampin
What this could lead to
If successful, this could lead to a shorter, 2-month treatment for latent TB, making it easier for people to complete therapy and prevent active TB.
What could go wrong
This is a Phase 2 trial, so results are preliminary. Higher doses may cause more side effects, and the shorter regimen might not be as effective as the standard 4-month course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1,368 people

The number who actually took part.

Started

Sep 2019

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults, and children aged 10 and older who weigh at least 25kg. * Evidence of latent TB infection: positive tuberculin skin test (5mm or greater or 10mm or greater, based on National guidelines) or positive interferon gamma release assay. * Eligible to take latent TB treatment according to Canadian guidelines in the Canadian sites, and according to World Health Organization (WHO) guidelines in the international sites (this includes household contacts, other contacts, HIV infected, other causes of immune suppression, fibronodular disease on chest-x ray (CXR), or other indication). Exclusion Criteria: * Children aged 0-9 and children aged 10 or older who weigh less than 25kg * Pregnancy * Baseline AST or ALT that is at least 3 times higher than upper limit of normal * Baseline Grade 3-4 abnormalities of hematological tests (WBC, platelets or hemoglobin). * Prior treatment for latent or active TB. * Rifampin contra-indicated - due to potential drug interactions that are considered too important, or difficult to manage, by health care provider; or due to history of allergy/ hypersensitivity to rifampin, rifabutin or rifapentine. * Household contacts of index TB patients with confirmed, or suspected rifampin resistant TB.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Latent tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Latent tuberculosis

Contacts and locations

Locations

  • BCCDC TB clinic

    Vancouver, British Columbia, Canada

  • Hai Ba Trung District Health Center, No. 16B

    Hà Nội, Vietnam

  • Hanoi Lung Hospital

    Hà Nội, Vietnam

  • MUHC

    Montreal, Quebec, H4A 3J1, Canada

  • Nam Tu Liem District Health Center, No. 3

    Hà Nội, Vietnam

  • Phoi Viet TB and Respiratory Diseases Clinic.

    Ho Chi Minh City, Vietnam

  • The Governors of the University of Alberta

    Edmonton, Alberta, T6G 2C8, Canada

  • Universitas Padjadjaran, Klinik Penelitian Tuberculosis (TB research clinic)

    Bandung, Indonesia

  • Unviversity of Calgary

    Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.